This is a working overview of TB-500, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-24 and is reviewed periodically as new material appears.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (dry) | -20 °C | Protected from light and moisture |
| Storage temperature (solution) | -80 °C | Single-use aliquots recommended |
| Identity assay | LC-MS or MALDI-TOF | Confirms mass near 889 Da |
| Purity assay | RP-HPLC | Reports main peak percentage |
| Common impurities | Truncated peptides, deamidated forms | Arise from synthesis or storage |
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
==== Overview ==== In July 2012, GSK pleaded guilty in the United States to criminal charges, and agreed to pay US$3 billion, in what was the largest settlement until then between the Justice Department and a drug company. The US$3 billion included a criminal fine of US$956,814,400 and forfeiture of US$43,185,600. The remaining US$2 billion covered a civil settlement with the government under the False Claims Act. The investigation was launched largely on the basis of information from four whistleblowers who filed qui tam (whistleblower) lawsuits against the company under the False Claims Act. The charges stemmed from GSK's promotion of the anti-depressants Paxil (paroxetine) and Wellbutrin (bupropion) for unapproved uses from 1998 to 2003, specifically as suitable for patients under the age of 18, and from its failure to report safety data about Avandia (rosiglitazone), both in violation of the Federal Food, Drug, and Cosmetic Act. Other drugs promoted for unapproved uses were two inhalers, Advair (fluticasone/salmeterol) and Flovent (fluticasone propionate), as well as Zofran (ondansetron), Imitrex (sumatriptan), Lotronex (alosetron) and Valtrex (valaciclovir). The settlement also covered reporting false best prices and underpaying rebates owed under the Medicaid Drug Rebate Program, and kickbacks to physicians to prescribe GSK's drugs. There were all-expenses-paid spa treatments and hunting trips for doctors and their spouses, speakers' fees at conferences, and payment for articles ghostwritten by the company and placed by physicians in medical journals.
Neither the patient nor the healthcare provider knew which treatment was being given until after the trials. Treatment was given for 40 weeks. In the other three trials (NCT3987919, NCT03882970, and NCT03730662), participants were randomly assigned to receive either tirzepatide or another antidiabetic medication, and both the patient and the provider knew which medication was being given. Treatment was given for 40 weeks to 104 weeks. In each trial, HbA1c was measured from the start to the end of the trial and compared between the tirzepatide group and the other groups. Tirzepatide's efficacy for chronic weight management (weight reduction and maintenance) in combination with a reduced-calorie diet and increased physical activity was established in two randomized, double-blind, placebo-controlled trials in adults with obesity or overweight who had at least one weight-related condition. These studies measured weight reduction after 72 weeks in 2,519 participants who received either 5, 10, or 15 mg of tirzepatide once weekly and 958 participants who received weekly placebo injections. In both trials, after 72 weeks of treatment, participants who received tirzepatide at all three dose levels experienced a statistically significant reduction in body weight compared to those who received placebo, and greater proportions of participants who received tirzepatide achieved at least 5% weight reduction compared to placebo.
=== Pharmacokinetics === The pharmacokinetics of SR-17018 in rodents have been studied. In mice, it is orally active, showing 69% bioavailability, has an elimination half-life of approximately 6 hours, and efficiently crosses the blood–brain barrier into the central nervous system. The drug has greatly improved bioavailability orally compared to intraperitoneally in mice. Its half-life in mice is longer than that of morphine or oxycodone. Similarly, its duration is longer than that of morphine or fentanyl in mice.
=== New Zealand === On 12 March, the New Zealand Government released six days' worth of petroleum following a global directive by the International Energy Agency to release 400 million barrels of petrol in response to supply disruptions caused by the 2026 Iran war. On 24 March, the New Zealand Government announced that about 143,000 working families with children would receive a $50 tax credit to help with rising fuel costs from 7 April. Another 14,000 families were also expected to be eligible for a lower tax credit. On 27 March, the New Zealand Government released its four-level fuel alert level system in response to fuel shortages caused by the Iran conflict. That day the country was placed on the first phase, watchful, with the public advised to use fuel cautiously.
The word(s) of the year, sometimes capitalized as "Word(s) of the Year" and abbreviated "WOTY" (or "WotY"), refers to any of various assessments as to the most important word(s) or expression(s) in the public sphere during a specific year. The German tradition Wort des Jahres was started in 1971. In 1999 it was supplemented with the Austrian word of the year to express the pluricentric nature of German and its multiple standards varieties. The American Dialect Society's Word of the Year is the oldest English-language version, and the only one that is announced after the end of the calendar year, determined by a vote of independent linguists, and not tied to commercial interest. However, various other organizations also announce Words of the Year for a variety of purposes.
Sources: en.wikipedia.org
== Education and academic career == Ben-Tal studied biology, chemistry, and physics at the Hebrew University of Jerusalem, receiving his bachelor's degree in 1988. He subsequently earned a D.Sc. in chemistry from the Technion – Israel Institute of Technology in 1993, under the supervision of Professor Nimrod Moiseyev. He completed postdoctoral training with Professor Barry Honig in biophysical chemistry and computational biophysics at Columbia University in New York. In 1997, Ben-Tal joined the Department of Biochemistry and Molecular Biology at Tel Aviv University. He became a full professor in 2007. He is a member of the university's School of Neurobiology, Biochemistry and Biophysics and also serves as head of the Bioinformatics Master program within the Faculty of Life Sciences. In 2018, Ben-Tal was awarded the Abraham E. Kazan Chair of Structural Biology at Tel Aviv University.
=== Commanding officers === 1950 Lt Col Mike Calvert, Royal Engineers 1951 Lt Col John Sloane, Argyll and Sutherland Highlanders 1953 Lt Col Oliver Brooke, Welch Regiment 1954 Lt Col Michael Osborn, West Yorkshire Regiment 1955 Lt Col George Lea, Lancashire Fusiliers and Parachute Regiment 1957 Lt Col Tony Deane-Drummond, Royal Signals 1960 Lt Col Ronald Dare Wilson, Royal Northumberland Fusiliers 1962 Lt Col John Woodhouse, Dorset Regiment and East Surreys 1965 Lt Col Michael Wingate-Gray, Black Watch 1967 Lt Col John Slim, Argyll and Sutherland Highlanders 1969 Lt Col John Watts, Royal Irish Rangers 1972 Lt Col Peter de la Billière, Light Infantry 1974 Lt Col Anthony Jeapes, Devonshire and Dorset Regiment 1977 Lt Col Mike Wilkes, Royal Artillery 1982 Lt Col Mike Rose, Coldstream Guards 1984 Lt Col Andrew Massey, Royal Corps of Transport 1986 Lt Col Cedric Delves, Devonshire and Dorset Regiment 1989 Lt Col John Holmes, Scots Guards n/k Lt Col Jonathan "Jacko" Page, Parachute Regiment 2001 Lt Col Ed Butler, Royal Green Jackets 2002 Lt Col Mark Carleton-Smith, Irish Guards 2007 Lt Col Richard Williams, Parachute Regiment 2012 Lt Col Nick Perry, King's Royal Hussars
The role of astrocytes in CNS regeneration following injury is not well understood though. The glial scar has traditionally been described as an impermeable barrier to regeneration, thus implicating a negative role in axon regeneration. However, recently, it was found through genetic ablation studies that astrocytes are actually required for regeneration to occur. More importantly, the authors found that the astrocyte scar is actually essential for stimulated axons (that axons that have been coaxed to grow via neurotrophic supplementation) to extend through the injured spinal cord. Astrocytes that have been pushed into a reactive phenotype (termed astrogliosis, defined by the upregulation of among others, GFAP and vimentin expression, a definition still under debate) may actually be toxic to neurons, releasing signals that can kill neurons. Much work, however, remains to elucidate their role in nervous system injury. Long-term potentiation: There is debate among scientists as to whether astrocytes integrate learning and memory in the hippocampus. Recently, it has been shown that engrafting human glial progenitor cell in nascent mice brains causes the cells to differentiate into astrocytes. After differentiation, these cells increase LTP and improve memory performance in the mice. Circadian clock: Astrocytes alone are sufficient to drive the molecular oscillations in the SCN and circadian behavior in mice, and thus can autonomously initiate and sustain complex mammalian behavior.
British importer BBH Spirits began to import Hill's Absinth from the Czech Republic in the 1990s, as the UK had never formally banned it, and this sparked a modern resurgence in its popularity. It began to reappear during a revival in the 1990s in countries where it was never banned. Forms of absinthe available during that time consisted almost exclusively of Czech, Spanish, and Portuguese brands that were of recent origin, typically consisting of Bohemian-style products. Connoisseurs considered these of inferior quality and not representative of the 19th-century spirit. In 2000, La Fée Absinthe became the first commercial absinthe distilled and bottled in France since the 1914 ban, but it is now one of dozens of brands that are produced and sold within France. In the Netherlands, the restrictions were challenged by Amsterdam wine seller Menno Boorsma in July 2004, thus confirming the legality of absinthe once again. Similarly, Belgium lifted its long-standing ban on 1 January 2005 citing a conflict with the adopted food and beverage regulations of the single European Market. In Switzerland, the constitutional ban was repealed in 2000 during an overhaul of the national constitution although the prohibition was written into ordinary law instead. That law was later repealed, and absinthe was made legal on March 1, 2005. The drink was never officially banned in Spain although it began to fall out of favour in the 1940s and almost vanished into obscurity. Catalonia has seen a significant resurgence since 2007 when one producer established operations there.
Antifungals are used to kill or prevent further growth of fungi. In medicine, they are used as a treatment for infections such as athlete's foot, ringworm and thrush and work by exploiting differences between mammalian and fungal cells. Unlike bacteria, both fungi and humans are eukaryotes. Thus, fungal and human cells are similar at the molecular level, making it more difficult to find a target for an antifungal drug to attack that does not also exist in the host organism. Consequently, there are often side effects to some of these drugs. Some of these side effects can be life-threatening if the drug is not used properly. As well as their use in medicine, antifungals are frequently sought after to control indoor mold in damp or wet home materials. Sodium bicarbonate (baking soda) blasted on to surfaces acts as an antifungal. Another antifungal solution applied after or without blasting by soda is a mix of hydrogen peroxide and a thin surface coating that neutralizes mold and encapsulates the surface to prevent spore release. Some paints are also manufactured with an added antifungal agent for use in high humidity areas such as bathrooms or kitchens. Other antifungal surface treatments typically contain variants of metals known to suppress mold growth e.g. pigments or solutions containing copper, silver or zinc. These solutions are not usually available to the general public because of their toxicity.
Sources: en.wikipedia.org
The dry powder is normally kept at -20 °C, protected from light and moisture. Reconstituted solutions are often divided into aliquots and stored at -80 °C to reduce freeze-thaw damage.
Reverse-phase HPLC assesses purity, and mass spectrometry confirms molecular mass. The combination helps distinguish the target peptide from truncated or modified impurities.
Buffer composition, pH, adsorption to containers, and freeze-thaw history can all affect the amount of intact peptide in solution. These factors may change results even when the starting material is chemically correct.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.